Related Experiment Video
Updated: Jun 5, 2026
10:21
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
[Cardiac hypertrophy and changes in contractile function of cardiomyocyte]
Yan Chen1, Yun-Ying Wang, Lan-Ning Zhang
1Department of Aerospace Physiology, the Fourth Military Medical University, Xi'an 710032, China.
Sheng Li Xue Bao : [Acta Physiologica Sinica]
|December 21, 2010
Summary
Cardiac hypertrophy in rats progresses with increased cardiomyocyte size and sarcomere number. However, contractile function declines in later stages, suggesting molecular changes contribute to heart failure transition.
Area of Science:
- Cardiovascular Biology
- Cellular Physiology
- Pathophysiology
Context:
- Pressure-overload cardiac hypertrophy is a precursor to heart failure.
- Understanding the cellular transition from hypertrophy to failure is crucial for therapeutic development.
Purpose:
- To investigate the cellular mechanisms underlying the transition of pressure-overload cardiac hypertrophy to heart failure.
- To analyze morphological and contractile changes in cardiomyocytes over time in a rat model.
Summary:
- Transverse abdominal aortic constriction (TAC) in rats induced progressive cardiac hypertrophy, evidenced by increased cardiomyocyte length, width, and surface area.
- While sarcomere number increased, contractile function (shortening amplitude) was initially enhanced but significantly reduced in later stages (16- and 20-week TAC).
- Fibrosis formation appeared to constrain cardiomyocyte surface area increase in late-stage TAC, and reduced contractility suggests intrinsic molecular alterations.
Impact:
- This study elucidates key cellular events in the progression of cardiac hypertrophy towards heart failure.
- Findings highlight the dissociation between cardiomyocyte size and function in advanced stages.
- Suggests potential molecular targets for mitigating heart failure progression in hypertrophic conditions.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...